HeartBeam, a medical technology company focused on advancing cardiac care, announced the appointment of Bryan Humbarger as chief commercial officer, effective January 22, 2026. In this newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives for the company.
The appointment comes as HeartBeam prepares for the limited launch of its recently cleared HeartBeam System. This system includes technology for arrhythmia assessment and heart attack detection, along with a 12-lead ECG extended wear patch monitor. Humbarger's responsibilities will include expanding outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption of the technology.
HeartBeam is creating what it describes as the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located, delivering what the company calls "actionable heart intelligence." The technology aims to enable physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of traditional medical facilities.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-Lead ECG synthesis software receiving clearance in December 2025. According to the company's Cleared Indications for Use available at https://www.heartbeam.com/indications, the technology has specific intended applications that have received regulatory approval.
For business and technology leaders, this appointment signals HeartBeam's transition from technology development to commercial deployment in the growing digital health market. The company's approach to cardiac monitoring represents a shift toward decentralized healthcare delivery, where critical diagnostic capabilities move from clinical settings to patients' everyday environments. This could potentially reduce healthcare costs while improving access to timely cardiac assessments.
The commercial strategy led by Humbarger will focus on establishing clinical validation through partnerships with cardiology practices, which could accelerate adoption in both clinical and consumer health markets. As the company moves toward broader commercialization, industry observers will be watching how this technology performs in real-world settings and whether it can deliver on its promise of transforming cardiac health management.
Investors and industry professionals can find additional information about the company's developments in its newsroom at https://ibn.fm/BEAT. The appointment of a dedicated commercial leader suggests HeartBeam is preparing for significant market expansion of its cardiac monitoring technology in the coming years.
